Literature DB >> 14872483

A TNFR1 genotype with a protective role in familial rheumatoid arthritis.

Philippe Dieudé1, José Osorio, Elisabeth Petit-Teixeira, Sarah Moreno, Sophie Garnier, Séverine Cailleau-Moindrault, Caroline Stalens, Sandra Lasbleiz, Thomas Bardin, Bernard Prum, François Cornélis.   

Abstract

OBJECTIVE: Results of genome scans in rheumatoid arthritis (RA) have suggested that the tumor necrosis factor receptor I (TNFRI) and TNFRII loci (TNFR1 and TNFR2) are susceptibility loci. A TNFR2 polymorphism was found to be associated with familial RA. TNFR1 is mutated in TNFR-associated periodic syndrome (TRAPS). We undertook this study to test the TNFR1 exonic polymorphism closest to the TRAPS mutations site (+36 A/G) for association with RA.
METHODS: DNA samples were available from two groups of the French Caucasian population: 1) 100 families with 1 RA patient and both parents and 2) 86 RA index patients from families with at least 2 siblings with RA (affected sibpairs [ASPs]). The +36 A/G polymorphism of TNFR1 was genotyped by polymerase chain reaction-restriction fragment length polymorphism. The analysis was performed using the transmission disequilibrium test, the genotype relative risk, and a linkage-based test previously described.
RESULTS: A negative association between RA and the +36 A/A genotype, suggested in the first sample (P = 0.084), was demonstrated in the second (ASP RA) sample (odds ratio [OR] 0.465; P = 0.012) and confirmed by the linkage-based test (OR 0.17; P = 0.008). The protective genotype, present in 41% of controls, was less frequent in RA patients: 33% in the first sample, 24% in the ASP RA sample, and 11% in the linkage-derived subgroup. Distribution of both TNFR2 196 R/R and TNFR1 +36 A/A genotypes in the ASP RA sample showed that both suspected genotypes were exclusive.
CONCLUSION: We found evidence for an association between RA and a TNFR1 protective genotype, restricted to familial RA. Distribution of the TNFR2 196 R/R and TNFR1 +36 A/A genotypes in familial RA could suggest an interaction between TNFR1 and TNFR2 in the genetic susceptibility for RA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14872483     DOI: 10.1002/art.20055

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

1.  Tumor necrosis factor (TNF) and TNFR1 polymorphisms are not risk factors for rheumatoid arthritis in a Mexican population.

Authors:  Daniel Cadena-Sandoval; Isidro Alemán-Ávila; Rosa Elda Barbosa-Cobos; Lizbeth Teresa Becerril-Mendoza; José Manuel Fragoso; Julián Ramírez-Bello
Journal:  Mol Biol Rep       Date:  2018-02-05       Impact factor: 2.316

2.  -383 A/C tumor necrosis factor receptor 1 polymorphism and ankylosing spondylitis in Mexicans: a preliminary study.

Authors:  Esther Guadalupe Corona-Sanchez; José Francisco Muñoz-Valle; Laura Gonzalez-Lopez; Julia Dolores Sanchez-Hernandez; Monica Vazquez-Del Mercado; Heriberto Ontiveros-Mercado; Miguel Huerta; Xochitl Trujillo; Alberto Daniel Rocha-Muñoz; Alfredo Celis; Ricardo Ortega-Flores; Jorge Ivan Gamez-Nava
Journal:  Rheumatol Int       Date:  2011-07-26       Impact factor: 2.631

3.  The TNFRSF1A R92Q mutation is frequent in rheumatoid arthritis but shows no evidence for association or linkage with the disease.

Authors:  Philippe Dieudé; Michel Goossens; François Cornélis; Laëtitia Michou; Thomas Bardin; Dimitri Olegovitch Tchernitchko
Journal:  Ann Rheum Dis       Date:  2007-01-18       Impact factor: 19.103

4.  The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis.

Authors:  Frauke Stanke; Tim Becker; Harry Cuppens; Vinod Kumar; Jean-Jacques Cassiman; Silke Jansen; Dragica Radojkovic; Benny Siebert; Jennifer Yarden; David W Ussery; Thomas F Wienker; Burkhard Tümmler
Journal:  Hum Genet       Date:  2006-02-04       Impact factor: 4.132

5.  Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.

Authors:  John R Glossop; Peter T Dawes; Nicola B Nixon; Derek L Mattey
Journal:  Arthritis Res Ther       Date:  2005-09-07       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.